Abstract Details

Title Persistence with multiple sclerosis disease-modifying therapies is highest when switching to fingolimod compared with other oral and injectable therapies: a retrospective US claims database analysis

Topic Multiple Sclerosis

Presentation(s) P2 - (-)

Poster/Presentation
Number 397

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
PRESENTER	No disclosure on file
Jennie Medin	No disclosure on file
Juanzhi Fang (EMD Serono)	No disclosure on file
Norman Putzki, MD (Novartis Pharma AG)	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��